Millions of Medicare beneficiaries with diabetes, heart failure, and other chronic conditions now have access to a fast-growing category of specialized coverage. Enrollment in Chronic Condition Special Needs Plans, known as C-SNPs, jumped 45 percent this year, according to the monthly SNP Comprehensive Report series published by the Centers for Medicare and Medicaid Services. The surge far outpaced growth in dual-eligible and institutional SNP categories, concentrating in a small number of large contracts and raising pointed questions about whether federal quality oversight can keep up.
Why the 45 percent C-SNP surge demands scrutiny now
C-SNPs are Medicare Advantage plans designed for people who have specific severe or disabling chronic conditions. They tailor benefits, provider networks, and care coordination to those diagnoses. The speed of this year’s enrollment increase matters because it signals that insurers are aggressively expanding these products while regulators are still calibrating how to measure their performance against standard Medicare Advantage benchmarks.
One way to test whether this growth is paired with genuine care-model innovation is to compare states with the largest C-SNP increases against contracts participating in the CMS Value-Based Insurance Design model. VBID flexibility allows plans to offer supplemental benefits and reduced cost-sharing for chronically ill enrollees. If the states driving C-SNP growth also show above-average VBID participation in the same contracts, that would suggest the enrollment spike reflects deliberate benefit design rather than simple marketing volume. The data to run that comparison exists in the May 2026 Medicare Advantage enrollment files broken out by state, county, and contract, alongside the CMS VBID participant list, but no published analysis has yet linked the two.
For beneficiaries, the stakes are high. C-SNPs can offer disease management programs, more frequent follow-up visits, and targeted drug coverage that traditional Medicare or standard Medicare Advantage plans may not match. Yet these same features make it harder for regulators and researchers to determine whether enrollees are receiving measurably better outcomes or simply being steered into narrow networks that may not be sustainable over time. A 45 percent jump in a single year magnifies the risk that oversight frameworks will lag behind business strategies.
CMS data and MedPAC findings behind the enrollment spike
The primary evidence sits in CMS’s own reporting infrastructure. The agency publishes a recurring set of special needs plan files each month, breaking enrollment into three plan types: C-SNPs for chronic conditions, D-SNPs for dual-eligible beneficiaries, and I-SNPs for people living in institutional settings. The reports also identify contracts, parent organizations, and state-level distribution, allowing analysts to see which insurers are driving the gains.
The May 2026 snapshot provides the most current view of this shift. Comparing that file against the January 2026 baseline shows that nearly all of the net new C-SNP enrollment is clustered in a handful of multi-state contracts. Looking back to January 2025 in the same series confirms that this is not a gradual, multi-year trend but a concentrated jump over the most recent plan year.
Separately, the Medicare Payment Advisory Commission presented findings on institutional special needs plans on April 10, 2026. That MedPAC analysis examined how network-adequacy requirements and star ratings apply unevenly across specialized plan types. While the session focused on I-SNPs, its conclusions carry direct implications for C-SNPs: plans serving complex populations often operate under rules that were built for more general Medicare Advantage products, leaving gaps in how CMS evaluates access, quality, and outcomes.
MedPAC highlighted that star ratings may not fully capture performance for beneficiaries with multiple chronic conditions, especially when those ratings rely heavily on measures that are difficult to interpret for highly specialized populations. If C-SNPs inherit the same framework without adjustment, a rapid enrollment spike could push hundreds of thousands of vulnerable enrollees into plans whose quality scores are only loosely tied to the care they actually receive.
Oversight challenges as C-SNPs scale
The concentration of C-SNP growth in a small number of large contracts intensifies oversight challenges. When a single parent organization controls a disproportionate share of enrollment, CMS must ensure that network adequacy, care coordination, and grievance processes are robust across every region where the plan operates. The MedPAC findings on uneven application of network rules suggest that current tools may not be finely tuned enough for that task.
Moreover, the same benefit design flexibility that makes C-SNPs attractive can obscure whether enrollees are getting appropriate specialist access or simply facing tighter utilization management. Without condition-specific quality metrics and transparent reporting on outcomes such as hospitalization rates, medication adherence, and functional status, regulators and beneficiaries alike are left to infer performance from incomplete signals.
What policymakers and analysts should watch next
As the 2027 plan-bid cycle approaches, policymakers will need to decide whether to refine C-SNP standards in light of this year’s enrollment surge. That could include developing more tailored quality measures, aligning star ratings with the realities of chronic disease management, and tightening network rules for plans that market aggressively to high-need populations. It may also require closer alignment between VBID experiments and permanent C-SNP regulations so that successful care models can scale safely.
For now, the CMS SNP reports and MedPAC’s recent work provide an early warning system rather than definitive answers. The 45 percent spike in C-SNP enrollment is not inherently a problem; it could reflect overdue expansion of specialized care for people who need it most. But without faster, more condition-specific oversight, the system risks confusing rapid growth with genuine improvement in care for chronically ill Medicare beneficiaries.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
